According to the company, data showed that the combination drug had a 46% overall response rate, a 69% disease control rate, and a 12-month overall survival rate of 77%.
Botensilimab was also found to be well-tolerated, with no grade 4 or 5 treatment-related adverse events. Safety profile was found to be similar to what has been previously reported in a phase 1 botensilimab program, the company said.
"We are advancing multiple randomized Phase 2 trials to evaluate the therapeutic potential of this agent across a range of solid tumors," Agenus Chief Medical Officer Steven O'Day said.
Price: 3.22, Change: -0.04, Percent Change: -1.08
|Research Alert: CFRA Maintains Hold Rating On Shares...|
|Sector Update: Health Care|
|Falling Consumer Confidence Ahead of Slowdown in Fed...|
|Westrock Coffee to Develop New Distribution Center i...|
|Sector Update: Tech|